DIVISLAB2020-07-012020-09-30in-bse-fin:OneOperatingExpenses01Member DIVISLAB2020-07-012020-09-30in-bse-fin:FourOperatingExpenses01Member DIVISLAB2020-07-012020-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-07-012020-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-07-012020-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-07-012020-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2020-04-01 2021-03-31 2020-10-27 INR Lakhs Half yearly true Cash Flow Indirect Single segment Pharmaceuticals 2020-07-01 2020-09-30 Unaudited Consolidated 17493000000.00 136400000.00 17629400000.00 5392400000.00 2500000.00 367800000.00 1931800000.00 1600000.00 611300000.00 2387100000.00 10694500000.00 6934900000.00 0.00 6934900000.00 1467400000.00 271600000.00 1739000000.00 0.00 5195900000.00 0.00 0.00 0.00 0.00 5195900000.00 15200000.00 5211100000.00 5195900000.00 0.00 0.00 530900000.00 2 19.57 19.57 0.00 0.00 19.57 19.57 1.tThe above Statement of Consolidated unaudited financial results for the quarter and half year ended 30th September 2020, Statement of consolidated unaudited assets and liabilities as at 30th September, 2020 and Statement of consolidated unaudited cash flows for the half year ended 30th September, 2020(‘Consolidated Statement’) are prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under section 133 of the Companies Act 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 7th November, 2020. The same also were subjected to “limited review” by the Auditors of the Company and their report contains no qualification. n2.tThe consolidated unaudited results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG. n3.tThe group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108. n4.tThe Group does not have any discontinued operations and the Profit for the period represents the Profits from Continuing operations only. n5.tThe Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Group will continue to closely monitor for any material changes to future economic conditions. n6.tDetails of forex gain/(loss) are as given below: n ntQuarter endedtHalf Year endedtYear ended nt30.09.2020t30.06.2020t30.09.2019t30.09.2020t30.09.2019t31.03.2020 nForex gain/(loss)t(1563)t481t1317t(1082)t705t8211 nForex gain has been included in Other Income and loss has been included in Other Expenses n7.tFigures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current year’s classification. Single segment 2020-04-01 2020-09-30 Unaudited Consolidated 34797700000.00 261600000.00 35059300000.00 10035100000.00 40400000.00 2085600000.00 3770800000.00 3900000.00 1173300000.00 4405500000.00 21514600000.00 13544700000.00 0.00 13544700000.00 3345900000.00 82300000.00 3428200000.00 0.00 10116500000.00 0.00 0.00 0.00 0.00 10116500000.00 15600000.00 10132100000.00 10116500000.00 0.00 0.00 530900000.00 2 38.11 38.11 0.00 0.00 38.11 38.11 Other Expenses 2387100000.00 Other Expenses 4405500000.00 0.00 1644900000.00 -1653100000.00 0.00 470700000.00 2000000.00 0.00 -39300000.00 0.00 -487700000.00 0.00 -288900000.00 0.00 1173300000.00 0.00 0.00 -3500000.00 -7600000.00 -17400000.00 52700000.00 0.00 227400000.00 0.00 -26500000.00 0.00 0.00 0.00 22700000.00 0.00 614900000.00 14159600000.00 0.00 -2100000.00 0.00 2585200000.00 -300000.00 11576200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 446000000.00 1400000.00 3743200000.00 9740000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 246000000.00 0.00 0.00 0.00 5798200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 334000000.00 0.00 3600000.00 0.00 2100000.00 0.00 0.00 -339700000.00 17034700000.00 0.00 17034700000.00 431500000.00 17466200000.00